Business Context and Reporting Period
Company: Medpace Holdings, Inc. (MEDP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Medpace is a leading global clinical contract research organization (CRO) providing full-service Phase I-IV clinical development services to biotechnology, pharmaceutical, and medical device companies. The company operates across 46 countries with approximately 6,200 employees as of year-end 2025. Key therapeutic areas include Oncology, Metabolic, Cardiology, Central Nervous System (CNS), and Antiviral and Anti-infective (AVAI).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Net Revenue | $2,530.2 | $2,109.1 | +20.0% |
| Income from Operations | $534.9 | $446.9 | +19.7% |
| Net Income | $451.1 | $404.4 | +11.6% |
| Diluted EPS | $15.28 | $12.63 | +21.0% |
| Operating Margin | 21.1% | 21.2% | -0.1 bps |
| Effective Tax Rate | 16.8% | 15.0% | +1.8% |
| Cash and Cash Equivalents | $497.0 | $669.4 | -$172.4 |
| Backlog | $3,027.2 | $2,902.2 | +4.3% |
| Net New Business Awards | $2,646.8 | $2,230.0 | +18.7% |
Liquidity and Debt: The company reported no indebtedness as of December 31, 2025. It maintains an unsecured credit facility with a $10.0 million revolving line of credit, of which the full amount was available. Net cash provided by operating activities was $713.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased by $421.2 million (20.0%), driven primarily by strong activity in Metabolic, Oncology, and CNS therapeutic areas.
- Cost Structure: Total direct costs rose 21.8% to $1,769.6 million. This was largely due to a $266.8 million increase in reimbursed out-of-pocket expenses and higher personnel costs to support service growth.
- Share Repurchases: The company significantly increased buyback activity, repurchasing 2,961,924 shares for $912.9 million in 2025, compared to 527,160 shares for $174.2 million in 2024. This was the primary driver for the decrease in cash and cash equivalents.
- Tax Provision: The effective tax rate increased to 16.8% from 15.0%, attributed to decreased tax benefits related to Foreign Derived Intangible Income (FDII) and increased Global Intangible Low-Taxed Income (GILTI).
- Backlog: Backlog increased by $125.0 million to $3,027.2 million, with approximately $1.9 billion expected to convert to revenue in 2026.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted the disciplined operating model and full-service approach as key differentiators. The company expects to continue expanding operations through organic growth and selective bolt-on acquisitions. Capital spending as a percentage of revenue decreased to 1.24% in 2025.
Outlook: The company anticipates sufficient liquidity to fund operations for the next 12 months and beyond through operating cash flows and existing credit facilities. No specific numerical guidance for 2026 revenue or earnings was provided in this text.
Key Risks:
- Contract Termination: Customers can terminate contracts without cause upon 30 days' notice, creating revenue volatility.
- Customer Concentration: While no single customer exceeded 10% of revenue, the top ten customers accounted for approximately 35.1% of net revenue.
- Fixed-Fee Risk: The majority of contracts are fixed-fee; underpricing or cost overruns can materially impact profitability.
- Regulatory and Cybersecurity: Operations are subject to strict global regulations (FDA, EMA, HIPAA, GDPR) and face risks related to data security and system failures.
- Related Party Transactions: The CEO controls approximately 19.0% of outstanding common stock and has significant related party transactions, including real estate leases and service agreements with entities he controls.
Investor Verification Checklist
- Backlog Conversion Rate: Verify the historical conversion rate of backlog to revenue to assess the reliability of the $3.0 billion backlog figure.
- Share Repurchase Impact: Analyze the impact of the $912.9 million in share repurchases on future liquidity and capital allocation strategy.
- Related Party Leases: Review the terms of the real estate leases with entities owned by the CEO to ensure market-rate pricing.
- Customer Concentration: Monitor the top ten customers, which represent 35.1% of revenue, for any signs of contract reduction or termination.
- Tax Rate Volatility: Track the effective tax rate given the changes in FDII benefits and GILTI impacts noted in the 2025 filing.